Grimmsmann Thomas, Himmel Wolfgang
German Health Insurance Medical Service (MDK) Mecklenburg-Vorpommern, Schwerin, Germany.
Department of General Practice, Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.
BMJ Open. 2016 Nov 22;6(11):e011650. doi: 10.1136/bmjopen-2016-011650.
The aim of the study was to compare therapy persistence among patients who started with one of three drug regimens: a monotherapy, or combination therapy either as a fixed combination (ie, 'single pill') or as a free combination (ie, two separate antihypertensive agents).
In a secondary data analysis, we used descriptive statistics and multivariate logistic regression to measure the effect of the three therapy regimens on therapy persistence over 4 years.
Prescription data from a large German statutory health insurance provider.
All patients who started with a new antihypertensive therapy in 2007 or 2008 (n=8032) were included and followed for 4 years.
Therapy persistence, defined as receiving a refill prescription no later than within 180 days.
The persistence rates after 4 years were nearly identical among patients who started with a monotherapy (40.3%) or a fixed combination of two drugs (39.8%). However, significantly more patients who started with free-drug combinations remained therapy persistent (56.4%), resulting in an OR of 2.00 (95% CI 1.6 to 2.5; p<0.0001) for free combinations versus fixed combinations. This trend was observed in all age groups and for men and women. At the end of the study period, the number of different antihypertensive agents was still similar between patients who started with a fixed combination (2.41) and patients who started with a free combination (2.28).
While single-pill combinations make it easier to take different drugs at once, the risk is high that these several substances are stopped at once. Therapy persistence was significantly better for patients who started with a free-drug combination without taking much fewer different antihypertensive drugs as those with a fixed combination.
本研究旨在比较起始采用三种药物治疗方案之一的患者的治疗持续性,这三种方案分别为:单药治疗,或固定复方(即“单片”)联合治疗,或自由联合治疗(即两种单独的抗高血压药物)。
在一项二次数据分析中,我们使用描述性统计和多变量逻辑回归来衡量这三种治疗方案对4年治疗持续性的影响。
来自德国一家大型法定医疗保险机构的处方数据。
纳入所有在2007年或2008年开始新抗高血压治疗的患者(n = 8032),并随访4年。
治疗持续性,定义为在不迟于180天内获得续方。
起始采用单药治疗(40.3%)或两种药物固定复方治疗(39.8%)的患者4年后的持续性率几乎相同。然而,起始采用自由联合治疗的患者治疗持续性显著更高(56.4%),自由联合治疗与固定复方治疗相比的优势比为2.00(95%置信区间1.6至2.5;p<0.0001)。在所有年龄组以及男性和女性中均观察到这一趋势。在研究期末,起始采用固定复方治疗的患者与起始采用自由联合治疗的患者之间使用的不同抗高血压药物数量仍相似(分别为2.41种和2.28种)。
虽然单片复方使同时服用不同药物变得更容易,但这些几种药物同时停用的风险很高。起始采用自由联合治疗的患者治疗持续性显著更好,且与采用固定复方治疗的患者相比,使用的不同抗高血压药物数量并没有少很多。